Skip to main content
Triangle logo TriangleGet started

Rina-S (NCT07288177)

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer: a one-minute explainerNCT072881771 min

Rina-S trial for Non-small Cell Lung Cancer (NSCLC) (NCT07288177). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with advanced lung adenocarcinoma that progressed during or after their latest treatment and cannot receive curative surgery or radiation. Selected patients with or without actionable genetic alterations can join.

The idea: use Rina-S alone, infused into a vein. Its antibody targets folate receptor alpha to deliver a payload that disrupts DNA copying. Researchers measure tumor responses and safety. Only two of five groups use random dose assignment; every group receives treatment. Additional screening rules apply.

This phase 2 study plans 240 patients. Genmab sponsors twenty-one recruiting US sites.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.